WO2000019883A3 - Compositions and methods of disease diagnosis and therapy - Google Patents

Compositions and methods of disease diagnosis and therapy Download PDF

Info

Publication number
WO2000019883A3
WO2000019883A3 PCT/US1999/023418 US9923418W WO0019883A3 WO 2000019883 A3 WO2000019883 A3 WO 2000019883A3 US 9923418 W US9923418 W US 9923418W WO 0019883 A3 WO0019883 A3 WO 0019883A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
mutation
gene
detecting
blood
Prior art date
Application number
PCT/US1999/023418
Other languages
French (fr)
Other versions
WO2000019883A9 (en
WO2000019883A2 (en
Inventor
Timothy J Aitman
James Scott
Lawrence W Stanton
Original Assignee
Medical Res Council
Scios Inc
Timothy J Aitman
James Scott
Lawrence W Stanton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council, Scios Inc, Timothy J Aitman, James Scott, Lawrence W Stanton filed Critical Medical Res Council
Priority to EP99954782A priority Critical patent/EP1129217A4/en
Priority to AU11047/00A priority patent/AU776917B2/en
Priority to JP2000573246A priority patent/JP2003529315A/en
Priority to CA002346765A priority patent/CA2346765A1/en
Publication of WO2000019883A2 publication Critical patent/WO2000019883A2/en
Publication of WO2000019883A3 publication Critical patent/WO2000019883A3/en
Publication of WO2000019883A9 publication Critical patent/WO2000019883A9/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention pertains to isolated nucleic acid molecules containing sequences specified herein, to mutant CD36 genes and their encoded gene products, to methods of screening blood or a blood product by detecting a CD36 gene mutation, methods of administering blood or a blood product based on the presence or absence of a CD36 gene mutation, to methods of matching a biological sample donor with a recipient based on detection of a mutation in the CD36 gene, methods of determining the resistance of a patient to infection by a parasite by detecting a CD36 gene mutation, methods of diagnosing a disease associated with a defect in insulin action, glucose metabolism, fatty acid metabolism, and/or catecholamine action by detecting a mutation in the CD36 gene, and methods of disease treatment by altering the mutation(s).
PCT/US1999/023418 1998-10-07 1999-10-07 Compositions and methods of disease diagnosis and therapy WO2000019883A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99954782A EP1129217A4 (en) 1998-10-07 1999-10-07 Compositions and methods of disease diagnosis and therapy
AU11047/00A AU776917B2 (en) 1998-10-07 1999-10-07 Compositions and methods of disease diagnosis and therapy
JP2000573246A JP2003529315A (en) 1998-10-07 1999-10-07 Components and methods for disease diagnosis and treatment
CA002346765A CA2346765A1 (en) 1998-10-07 1999-10-07 Compositions and methods of disease diagnosis and therapy

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US16775098A 1998-10-07 1998-10-07
US22122298A 1998-12-28 1998-12-28
US09/270,542 1999-03-17
US09/167,750 1999-03-17
US09/221,222 1999-03-17
US09/270,542 US6322976B1 (en) 1998-05-28 1999-03-17 Compositions and methods of disease diagnosis and therapy

Publications (3)

Publication Number Publication Date
WO2000019883A2 WO2000019883A2 (en) 2000-04-13
WO2000019883A3 true WO2000019883A3 (en) 2000-09-08
WO2000019883A9 WO2000019883A9 (en) 2000-10-19

Family

ID=27389441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/023418 WO2000019883A2 (en) 1998-10-07 1999-10-07 Compositions and methods of disease diagnosis and therapy

Country Status (6)

Country Link
US (1) US6322976B1 (en)
EP (1) EP1129217A4 (en)
JP (1) JP2003529315A (en)
AU (1) AU776917B2 (en)
CA (1) CA2346765A1 (en)
WO (1) WO2000019883A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486299B1 (en) * 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
GB9927502D0 (en) * 1999-11-19 2000-01-19 Isis Innovation CD36 Polymorphisms
EP1162458A1 (en) * 2000-06-05 2001-12-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and compositions for modulating oxidized LDL transport
WO2002016947A2 (en) * 2000-08-21 2002-02-28 Queen's University At Kingston Methods and kits for separation and detection of proteins in biological samples
WO2002090979A1 (en) * 2001-05-08 2002-11-14 Histatek, Inc. Biochips and method of screening using drug induced gene and protein expression profiling
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040077567A1 (en) * 2002-10-16 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of CD36 expression
US20040076621A1 (en) * 2002-10-16 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of CD36 expression
CN1833034B (en) * 2003-06-20 2014-04-16 埃克斯魁恩公司 Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8080374B2 (en) * 2004-05-11 2011-12-20 Joslin Diabetes Center, Inc. Methods of diagnosing cardiovascular disease
ES2571929T3 (en) * 2004-05-26 2016-05-27 Region Nordjylland Procedure to determine the amount of circulating CD36
EP1754058B1 (en) * 2004-05-26 2016-04-13 Region Nordjylland Method for determining the amount of circulating CD36
US20070020657A1 (en) * 2005-05-20 2007-01-25 Grebe Stefan K Methods for detecting circulating tumor cells
JP5175501B2 (en) * 2006-11-15 2013-04-03 ニプロ株式会社 Test strip for detecting drug sensitivity in Mycobacterium tuberculosis
WO2009128734A1 (en) * 2008-04-18 2009-10-22 Vialactia Biosciences (Nz) Limited Marker assisted identification of mammals for desired phenotypic trait
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
CN103037901B (en) * 2010-06-01 2018-04-27 康奈尔大学 Suppress CD36 with obesity controlling and insulin sensitivity
WO2012149465A2 (en) * 2011-04-27 2012-11-01 Isis Pharmaceuticals, Inc. Modulation of cd36 expression

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006849A1 (en) * 1991-10-03 1993-04-15 The Center For Blood Research Binding of plasmodium falciparum-infected erythrocytes to cd36
US5338839A (en) * 1988-04-12 1994-08-16 Massachusetts Institute Of Technology DNA encoding nestin protein
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US5629158A (en) * 1989-03-22 1997-05-13 Cemu Bitecknik Ab Solid phase diagnosis of medical conditions
US5871931A (en) * 1995-06-30 1999-02-16 Millennium Pharmaceuticals, Inc. Methods for detecting mammalian tub protein and RNA

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2422956A1 (en) 1978-04-13 1979-11-09 Pasteur Institut METHOD OF DETECTION AND CHARACTERIZATION OF A NUCLEIC ACID OR OF A SEQUENCE OF THE SAME, AND ENZYMATIC REAGENT FOR THE IMPLEMENTATION OF THIS PROCESS
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
NO169351C (en) 1987-10-02 1992-06-10 Boerresen Anne Lise MASS TEST METHOD FOR THE DETECTION OF SINGLE BASE MUTIONS IN MULTIPLE LOCI IN GENOMIC DNA BY USING DENATURING GRADIENT GELELECTROPHORESIS EFFECTIVE OF EFFECTIVE TRANSFER AND HYBRIDIZATION FOR HYBRIDIZATION
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2093427C (en) * 1990-10-17 2008-01-15 Marvin S. Reitz, Jr. Molecular clones of hiv-1 and uses thereof
US5976789A (en) * 1991-07-17 1999-11-02 Bio Merieux System of probes enabling HLA-DR typing to be performed, and typing method using said probes
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5834183A (en) * 1993-06-29 1998-11-10 Regents Of The University Of Minnesota Gene sequence for spinocerebellar ataxia type 1 and method for diagnosis
AU8126694A (en) * 1993-10-26 1995-05-22 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
US5550020A (en) * 1994-07-08 1996-08-27 Visible Genetics Inc. Method, reagents and kit for diagnosis and targeted screening for retinoblastoma
US5992926A (en) * 1997-07-30 1999-11-30 Dana Corporation Vehicular skid plate and cross member assembly

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US5338839A (en) * 1988-04-12 1994-08-16 Massachusetts Institute Of Technology DNA encoding nestin protein
US5629158A (en) * 1989-03-22 1997-05-13 Cemu Bitecknik Ab Solid phase diagnosis of medical conditions
WO1993006849A1 (en) * 1991-10-03 1993-04-15 The Center For Blood Research Binding of plasmodium falciparum-infected erythrocytes to cd36
US5871931A (en) * 1995-06-30 1999-02-16 Millennium Pharmaceuticals, Inc. Methods for detecting mammalian tub protein and RNA

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
OHSHIMA ET AL.: "nucleotide sequence of the PR-1 gene of Nicotiana tabacum", FEBS LETTERS,, vol. 225, no. 1,2, 1987, pages 243 - 246, XP002928347 *
See also references of EP1129217A4 *
SILVERSTEIN ET AL.: "Sense and antisense cDNA transfection of CD36 (Glycoprotein IV) in melanoma cells", J. BIOL. CHEM.,, vol. 267, no. 23, 15 August 1992 (1992-08-15), pages 16607 - 16612, XP002928346 *

Also Published As

Publication number Publication date
AU776917B2 (en) 2004-09-23
WO2000019883A9 (en) 2000-10-19
AU1104700A (en) 2000-04-26
CA2346765A1 (en) 2000-04-13
US6322976B1 (en) 2001-11-27
WO2000019883A2 (en) 2000-04-13
EP1129217A2 (en) 2001-09-05
EP1129217A4 (en) 2005-04-20
JP2003529315A (en) 2003-10-07

Similar Documents

Publication Publication Date Title
WO2000019883A3 (en) Compositions and methods of disease diagnosis and therapy
US20180030516A1 (en) Microbiome Diagnostics
WO1997012992A3 (en) Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore
Shamim et al. Study of biochemical changes and elevated levels of enzymes in Salmonella typhi infected patients in Pakistani population
CN109182569A (en) The loop-mediated isothermal amplification detection method and kit of high virulence helicobacter pylori
Wenham et al. Insoluble glucan synthesis by mutansucrase as a determinant of the cariogenicity of Streptococcus mutans
Liu et al. Typing of mutans streptococci by arbitrarily primed PCR in patients undergoing orthodontic treatment
Lumb et al. Phenotypic and molecular characterization of three clinical isolates of Mycobacterium interjectum
CA2240737A1 (en) A long qt syndrome gene which encodes kvlqt1 and its association with mink
CN102952850B (en) Real-time fluorescent quantitative PCR method used for detecting Mycobacterium tuberculosis, and primer, probe and kit thereof
CN106661617A (en) Method for diagnosing hepatic fibrosis
CN1039722A (en) The diagnosis of the viral infection relevant and treatment with confirmed fatigue
Gill et al. An examination of ALDH2 genotypes, alcohol metabolism and the flushing response in Native Americans.
Kim et al. Comparison of gut microbiota between Sasang constitutions
Oladejo et al. Cytokine-mediated immunoregulatory activity of Lactobacillus species in a carrageenan-induced acute inflammatory model
Ling et al. Blood microbiota as a potential noninvasive diagnostic biomarker for liver fibrosis in severely obese patients: choose carefully
CN104830961B (en) For in vitro measuring the method for causing risk of obesity
Amalia et al. Hemoglobin and ferritin serum levels on leprosy patients before multi drug therapy-world health organization (Mdt-Who) compared with healthy control group
Peterson et al. Correlation of self-administered alcoholism screening test with hemoglobin-associated acetaldehyde
WO2016079735A1 (en) Bacteria donors and pharmaceutical compositions
CN105002172B (en) Detect application of the reagent of EAPP gene expressions in diagnosis and treatment Alzheimer disease
HUP0100674A2 (en) A dna molecule encoding a mutant prepro-neuropeptide y, a mutant signal peptide, and uses thereof
WO2005017197A3 (en) Method for early detection and monitoring of diseases by analysis of cell-surface-bound nucleic acids
CN1526023B (en) Use of primer and probe of aldose reductase gene in preparing composition for determination of risk factors for cataract
CN115261355B (en) AMPK alpha 1 succinylation modification and application

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 11047

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-127, DESCRIPTION, REPLACED BY NEW PAGES 1-123; PAGES 128-135, CLAIMS, REPLACED BY NEW PAGES124-130; PAGES 1/30-30/30, DRAWINGS, REPLACED BY NEW PAGES 1/30-30/30; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 11047/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2346765

Country of ref document: CA

Ref country code: JP

Ref document number: 2000 573246

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2346765

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999954782

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 1999954782

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 11047/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999954782

Country of ref document: EP